News

The highly anticipated data from the pivotal Phase III clinical trial is expected to yield final results in the third quarter of 2027. Subsequently, the company plans to complete the submission of its new drug application (NDA) to regulatory authorities in the second half of 2027. This progress marks a critical step toward commercializing the company's investigational therapy. Market analysts are closely watching the performance of data at this time point, as it will directly impact the approval prospects of the therapy and the company's future market valuation. Investors will closely follow further developments.

Ansem responded to the controversy surrounding creator tokens, denying any intention to conduct a $2 million rug pull. Ansem stated that their principle is to attract new users and provide liquidity through tokens, citing Dogecoin and BONK as examples. Dogecoin's market cap has reached $11 billion, and BONK revitalized the Solana ecosystem at the market bottom. Ansem emphasized that this is the first project in which they have led and held the majority of the token supply; in previous projects, several degen tokens were dumped due to anonymous teams hoarding tokens in advance.

On June 30, BlackRock's research arm noted in its Mid-Year Global Investment Outlook report for 2026 that it holds a cautious stance on emerging market stocks while being optimistic about short- and medium-term government bonds in the Eurozone. The report highlighted the concentration risks associated with artificial intelligence for the former. Regarding the latter, it suggested that concerns over interest rate prospects seem to be overblown. The world's largest asset management company has downgraded its rating for emerging market stocks over the next 6 to 12 months from 'overweight' to 'neutral.' The report pointed out risks in markets like South Korea, which are heavily reliant on AI-related companies.